Elotuzumab (anti-SLAMF7) | CD markers | Read Reviews & Product Use Citations

Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.

Click to purchase the isotype control of Elotuzumab (anti-SLAMF7)

Selleck's Elotuzumab (anti-SLAMF7) has been cited by 1 publication

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 10.96 mg/ml Endotoxin Level: ＜1EU/mg

99

Choose Selective CD markers Inhibitors

Biological Activity

Description	Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.

References
[1] Natalie A Bezman, et al. Blood Adv . 2017 May 8;1(12):753-765.

References

[1] Natalie A Bezman, et al. Blood Adv . 2017 May 8;1(12):753-765.

Product Details

CAS No.	915296-00-3
Molecular Weight	145 kD
Isotype	Human IgG1, κ
Source	CHO cells
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field